u/cormac_roos

Disagree. Inter-lab spread of a point or two on this assay is ordinary and calling it a discrepancy misleads people.

Yes. Retention time is a hypothesis about identity. Mass is the answer.

ask for the mass spectrum, not just the purity number

That figure cannot be quoted to two decimals off that baseline. The precision is not in the data.

appetite comes back before the weight does

Yes — system suitability first. Without it the number is an assertion about the instrument, not the sample.

Went up slowly, deliberately, because everything on this board says the escalation is where trouble lives. Uneventful so far and I am not going to pretend that is a finding.

Area percent is the integrated area of your peak over the total integrated area at one wavelength on one gradient. Change any of those and the number changes without the sample changing.

Not convinced. You are attributing a week of muscle cramps to the glucagon arm when the escalation rate alone would explain it.

triple agonist — GLP-1, GIP and glucagon, and the glucagon arm is the new part

Can you post the trace with the axes labelled?

stopping is a plan, not an event

Kept a log specifically because there is so little published. It is one person and it is not data.

the TRIUMPH programme is still running, so anything definitive is premature

What did the repeat show?

LC-MS for identity, UV for relative quantity

That reads as advice to stop, which is not something anyone here should be offering.

Mass spectrometry answers identity. UV purity answers relative quantity under the run conditions. A document with one and not the other is answering half the question, and the half it answers should be stated.

cost and supply are the two most common reasons and both are legitimate

Interval stretching lowers the trough concentration while keeping the dose; dose reduction lowers the level while keeping the rhythm. They are different interventions with different subjective profiles.

That is area percent, not mass percent. The trace cannot give you the second one.

wait for phase 3 before you argue about rankings

the escalation is where most of the reported trouble sits

Push back: that is a taper schedule aimed at another member and this board does not host those.

Watched heart rate on a wearable across twelve weeks because the threads said to. It moved a little and I have no idea whether that means anything.

Mass spectrometry answers identity. UV purity answers relative quantity under the run conditions. A document with one and not the other is answering half the question, and the half it answers should be stated.

I would not draw a line through two points, especially when the second was taken at a different time of day.

wait for phase 3 before you argue about rankings

Carryover from a previous high-concentration injection looks exactly like a small impurity. The blank injection is four minutes and it removes the ambiguity entirely.

Same lab as the previous draw?

Agreed — and standardising the draw conditions is the cheapest improvement available.

pentadecapeptide, fifteen residues, and the sequence is public

system suitability before you believe any number on the run

That reads as advice to stop, which is not something anyone here should be offering.

I would not treat appetite returning as a sign of doing it wrong. It is the expected sequence.

Careful — you are treating retention time as identity.

Disagreeing with this bit: that spread is ordinary inter-lab variance, not a disagreement about the material.

stopping is a plan, not an event

That comparison crosses two labs with different assays. The difference you are describing may be the method.

Careful. Regulatory status differs by jurisdiction and has changed; a confident global statement is going to be wrong somewhere.

Cosigning on baseline. The panel I regret most is the one I did not take before starting.

Wrote down where I was before changing anything. That single page made the following six months interpretable.